Anixa expands Cleveland Clinic joint development to develop additional cancer vaccines

Anixa Biosciences Inc

Anixa and Cleveland Clinic entered Joint Development and Option Agreement to develop vaccines for multiple cancers.
Anixa to pay non-refundable option fee and development funding in three tranches; first due May 8, 2024.
Option to obtain exclusive, royalty-bearing worldwide license to inventions developed under agreement.
Builds on existing breast cancer (Phase 1 TNBC) and ovarian cancer vaccine programs with Cleveland Clinic.
Research led by Dr. Thaddeus Stappenbeck and Dr. Justin Johnson at Cleveland Clinic.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Anixa Biosciences Inc entered into Joint Development and Option Agreement with Cleveland Clinic Foundation valued at Company will pay CCF a non-refundable, option fee on or before May 23, 2024, and development funding (effective 2024-05-03).

Action: entry
Agreement: collaboration
Counterparty: Cleveland Clinic Foundation
Value: Company will pay CCF a non-refundable, option fee on or before May 23, 2024, and development funding
Effective: 2024-05-03

Exact text from the filing

On May 3, 2024, Anixa Biosciences, Inc. (the “ Company ”) and the Cleveland Clinic Foundation (the “ CCF ”) entered into a Joint Development and Option Agreement (the “ Agreement ”). Pursuant to the Agreement, the parties agreed on the terms and conditions under which the parties will collaborate in efforts to develop vaccines for the prevention or treatment of cancers in the Fields.

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Anixa Biosciences Inc filing history →

Source: SEC EDGAR

accession 0001493152-24-018170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.